The Peter Zeihan Podcast Series Buying Time With Drugs || Peter Zeihan
10 snips
Mar 3, 2026 Discussion about whether current Alzheimer’s drugs can change global demographic trends. Examination of weight‑loss medications like Ozempic and their uncertain impact on population health. Argument that lasting longevity gains depend on lifelong lifestyle and social conditions, not quick pharmaceutical fixes.
AI Snips
Chapters
Transcript
Episode notes
Monoclonal Antibodies Won't Solve Aging Economics
- Monoclonal antibodies reduce Alzheimer’s cognitive decline but not enough to change demographics.
- They lower decline ~30% over 18 months and are costly, so they won't meaningfully extend workforce participation past current retirement ages.
Retirement Age Drives Demographic Pressure
- Cognitive and physical decline begins around age 59–60 and accelerates at 62–63, which is why retirement clusters at 65.
- To fix labor and tax shortfalls you need retirement ages pushed to ~70 plus treatments that preserve productivity through that span.
Too Late For Boomers To Benefit Economically
- Even if an effective anti-aging drug appeared today, most American baby boomers are already retired or nearly so.
- The youngest boomers are ~60, so only a small fraction could extend working lives; Gen X is too small to offset retiree numbers.